Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients

• Status: Unknown status
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine if amiloride, a diuretic drug, is capable of increasing renal salt excretion, lowering blood pressure and inhibiting uPA in kidney transplant recipients with proteinuria compared to normoalbuminuric transplant patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southern Denmark
• Collaborators: Odense University Hospital; Region of Southern Denmark
• Treatments: Amiloride

Criteria

Inclusion Criteria:

• One Group of kidney transplant recipients with ACR< 30mg/g

• One Group of kidney transplant recipients with ACR >300mg/g

• Negative pregnancy test at inclusion and taking contraceptive medication

Exclusion Criteria:

• Receiving amiloride, glucocorticoids, aldosterone or spironolactone

• Clinically relevant organic or systemic disease including malignancy

• eGFR or creatinin-clearance < 30ml/min

• hyperkalemia (s-potassium > 5,0mmol/l)